Cargando…

Naftopidil for the treatment of urinary symptoms in patients with benign prostatic hyperplasia

Naftopidil, approved only in Japan, is an α1-adrenergic receptor antagonist (α1-blocker) used to treat lower urinary tract symptoms (LUTS) suggestive of benign prostatic hyperplasia (BPH). Different from tamsulosin hydrochloride and silodosin, in that it has higher and extremely higher affinity resp...

Descripción completa

Detalles Bibliográficos
Autor principal:	Masumori, Naoya
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2011
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3132093/ https://www.ncbi.nlm.nih.gov/pubmed/21753885 http://dx.doi.org/10.2147/TCRM.S13883

Ejemplares similares

Comparative evaluation of naftopidil and tamsulosin in the treatment of patients with lower urinary tract symptoms with benign prostatic hyperplasia
por: Griwan, Mahavir Singh, et al.
Publicado: (2014)

Three-year outcome analysis of alpha 1-blocker naftopidil for patients with benign prostatic hyperplasia in a prospective multicenter study in Japan
por: Masumori, Naoya, et al.
Publicado: (2016)

The Persistence of Silodosin Monotherapy and the Reasons for Withdrawal from Treatment of Previously Untreated Japanese Patients with Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Hyperplasia
por: Tanaka, Yoshinori, et al.
Publicado: (2017)

Clinical Efficacy and Safety of Naftopidil Treatment for Patients with Benign Prostatic Hyperplasia and Hypertension: A Prospective, Open-Label Study
por: Chung, Mun Su, et al.
Publicado: (2017)

Involvement of magnitude of ambient temperature change in nonspecific effect in perceived placebo effect on lower urinary tract symptoms: study on switching of naftopidil in patients with benign prostatic hyperplasia
por: Morita, Tatsuo, et al.
Publicado: (2013)

The predictive factors of α1-D/A adrenoceptor antagonist, naftopidil, dose increase therapy for male lower urinary tract symptoms caused by benign prostatic hyperplasia: INFORM study
por: Tanuma, Yasushi, et al.
Publicado: (2017)

A comparison of the efficacy of naftopidil and tamsulosin hydrochloride in medical treatment of benign prostatic enlargement
por: Perumal, Chenthil, et al.
Publicado: (2015)

The Potential Role of Urinary Microbiome in Benign Prostate Hyperplasia/Lower Urinary Tract Symptoms
por: Yu, Seong Hyeon, et al.
Publicado: (2022)

The Add-On Effect of Solifenacin for Patients with Remaining Overactive Bladder after Treatment with Tamsulosin for Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Obstruction
por: Masumori, Naoya, et al.
Publicado: (2010)

Lower urinary tract symptoms and benign prostatic hyperplasia: From research to bedside
por: Goel, Apul
Publicado: (2019)

Current consensus and controversy on the treatment of male lower urinary tract symptoms/benign prostatic hyperplasia
por: Liao, Chun-Hou, et al.
Publicado: (2017)

Benign prostatic hyperplasia and male lower urinary symptoms: A guide for family physicians
por: Vasanwala, Farhad Fakhrudin, et al.
Publicado: (2017)

Inflammation is a target of medical treatment for lower urinary tract symptoms associated with benign prostatic hyperplasia
por: De Nunzio, Cosimo, et al.
Publicado: (2020)

Precision medicine in the diagnosis and treatment of male lower urinary tract symptoms suggestive of benign prostatic hyperplasia
por: Chen, Jing-Liang, et al.
Publicado: (2019)

Urinary microbiota in patients with prostate cancer and benign prostatic hyperplasia
por: Yu, Haining, et al.
Publicado: (2015)

Seasonal Variation of Urinary Symptoms in Korean Men with Lower Urinary Tract Symptoms and Benign Prostatic Hyperplasia
por: Choi, Ho Chul, et al.
Publicado: (2015)

The Urinary Tract Microbiome in Male Genitourinary Diseases: Focusing on Benign Prostate Hyperplasia and Lower Urinary Tract Symptoms
por: Kim, Myung Soo, et al.
Publicado: (2021)

Current consensus and controversy on the diagnosis of male lower urinary tract symptoms/benign prostatic hyperplasia
por: Lee, Cheng-Ling, et al.
Publicado: (2017)

Silodosin in the treatment of benign prostatic hyperplasia
por: Rossi, Maxime, et al.
Publicado: (2010)

Minimally invasive devices for treating lower urinary tract symptoms in benign prostate hyperplasia: technology update
por: Aoun, Fouad, et al.
Publicado: (2015)

The influence of asymptomatic inflammatory prostatitis on the onset and progression of lower urinary tract symptoms in men with histologic benign prostatic hyperplasia
por: Taoka, Rikiya, et al.
Publicado: (2017)

Newer Minimally Invasive Treatment Modalities to Treat Lower Urinary Tract Symptoms Attributed to Benign Prostatic Hyperplasia
por: Dahm, Philipp, et al.
Publicado: (2021)

Solifenacin/tamsulosin fixed-dose combination therapy to treat lower urinary tract symptoms in patients with benign prostatic hyperplasia
por: Dimitropoulos, Konstantinos, et al.
Publicado: (2015)

Add-on Therapy With the α-Blockers Tamsulosin and Naftopidil Improves Voiding Function by Enhancing Neuronal Activity in Prostatic Hyperplasia Rats
por: Ko, Il-Gyu, et al.
Publicado: (2018)

Depressive symptoms in patients diagnosed with benign prostatic hyperplasia
por: Pietrzyk, Barbara, et al.
Publicado: (2015)

Benign Prostatic Hyperplasia and Male Lower Urinary Tract Symptoms: Epidemiology and Risk Factors
por: Parsons, J. Kellogg
Publicado: (2010)

Relationship Between Chronic Periodontitis and Lower Urinary Tract Symptoms/Benign Prostatic Hyperplasia
por: Hyun, Hana, et al.
Publicado: (2021)

Is Increased Prostatic Urethral Angle Related to Lower Urinary Tract Symptoms in Males with Benign Prostatic Hyperplasia/Lower Urinary Tract Symptoms?
por: Park, Yoo Jun, et al.
Publicado: (2012)

Efficacy and safety of fexapotide triflutate in outpatient medical treatment of male lower urinary tract symptoms associated with benign prostatic hyperplasia
por: Shore, Neal, et al.
Publicado: (2019)

Alfuzosin for the medical treatment of benign prostatic hyperplasia and lower urinary tract symptoms: a systematic review of the literature and narrative synthesis
por: Mari, Andrea, et al.
Publicado: (2021)

New medical treatments for lower urinary tract symptoms due to benign prostatic hyperplasia and future perspectives
por: Albisinni, Simone, et al.
Publicado: (2016)

Therapeutic options in the treatment of benign prostatic hyperplasia
por: Sandhu, Jaspreet S
Publicado: (2009)

Recent advances in treatment for Benign Prostatic Hyperplasia
por: van Rij, Simon, et al.
Publicado: (2015)

Treatment of Benign Prostatic Hyperplasia by Natural Drugs
por: Csikós, Eszter, et al.
Publicado: (2021)

Autophagy deactivation is associated with severe prostatic inflammation in patients with lower urinary tract symptoms and benign prostatic hyperplasia
por: De Nunzio, Cosimo, et al.
Publicado: (2017)

The Impact of Illness Perceptions on Depressive Symptoms Among Benign Prostatic Hyperplasia Patients with Lower Urinary Tract Symptom
por: Yang, Linlin, et al.
Publicado: (2021)

The Urolift System for the Treatment of Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia: A NICE Medical Technology Guidance
por: Ray, Alistair, et al.
Publicado: (2016)

Benign prostatic hyperplasia: An overview of existing treatment
por: Dhingra, Neelima, et al.
Publicado: (2011)

Current Laser Treatments for Benign Prostatic Hyperplasia
por: Son, Hwancheol, et al.
Publicado: (2010)

Testosterone and benign prostatic hyperplasia
por: Jarvis, Thomas R, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_fgr82ooh093fvmqmop2m8dn9ut